Oorja Bio secured $30 million in a Series A round from founding investor Westlake Biopartners to advance its in-licensing drug pipeline for idiopathic pulmonary fibrosis (IPF) and other fibrotic and cardiopulmonary diseases. The company’s strategy is built around selecting and acquiring external assets rather than building from discovery. The funding supports pipeline progression and commercialization preparation across a disease area where late-stage development risk remains high and differentiation often hinges on fibrosis biology and functional outcomes. The round adds to the small-but-growing list of IPF financings aimed at translating anti-fibrotic activity into durable clinical benefit.